Clinical trial · no report yet · Phase 1
NCT04634539
Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
- NCT04634539 ↗
- Completed
- Jun Gong, MD
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- IIT2020-02-Gong-GlutaPanc: Phase I Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer (GlutaPanc)
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Advanced Pancreatic Adenocarcinoma; Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma
- Interventions
- Gemcitabine; Nab-paclitaxel; L-glutamine
- Arms
- Gemcitabine + Nab-paclitaxel + L-glutamine · Experimental
- Enrollment
- 18
- Primary outcomes
- Recommended phase II dose (RP2D) of combination gemcitabine, nab-paclitaxel, and L-glutamine in treatment-naive metastatic pancreatic cancer.
- Sponsor
- Jun Gong, MD with Emmaus Medical, Inc.
- Start
- May 13, 2021
- Primary completion
- Jul 6, 2023
- Results posted
- No
- Registry record
- NCT04634539 · updated Aug 6, 2025
Publications
linked from the registry- Gong J, Muranaka H, Choi SY, Tighiouart M, Bhute S, Aja ER, Jacobs JP, Stotland A, Van Eyk J, Elmadbouh OHM, Edderkaoui M, Tanaka S, Furuya H, Osipov A, Lorber J, Billet S, Morris A, Ten Hoeve-Scott J, Graeber T, Pandol SJ, Hendifar A, Bhowmick NA. L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial. Nat Cancer. 2026 Aug 31. doi: 10.1038/s43018-026-01225-z. Online ahead of print. PubMed 42675216